# Nuclide record tare-plus-durvalumab-hcc (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "tare-plus-durvalumab-hcc" ;
  schema:name "Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma"@en ;
  schema:description "Small early trials are giving liver-directed radiation beads (TARE) together with the immunotherapy drug durvalumab for liver cancer that cannot be operated on. Early results show high tumour shrinkage rates, but these are small studies and it is not yet proven that the combination helps people live longer than either treatment alone."@en ;
  schema:url <https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/37459133/>, <https://www.bostonscientific.com/content/dam/bsc/us/pi/ir/ioe/therasphere/downloads/TheraSphere-Systemic-Brochure.pdf>, <https://oncodaily.com/oncolibrary/immune-oncology/rowan-study-enrol-complet>, <https://clinicaltrials.gov/study/NCT06040099> ;
  nuclide:tag "hepatocellular carcinoma", "radioembolisation", "immunotherapy" ;
  nuclide:related <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/companies/sirtex/>, <https://nuclide.cc/companies/boston-scientific/>, <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/trials/nct05063565/>, <https://nuclide.cc/trials/nct06040099/>, <https://nuclide.cc/isotopes/y-90/> ;
  nuclide:pairs <https://nuclide.cc/technologies/radioembolisation-tare/>, <https://nuclide.cc/drugs/durvalumab/> .